Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Eli Lilly seeks to defend its interests in a lawsuit challenging the FDA's decision on the supply status of its drugs ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After ...

Encouraging primary care physicians to screen patients for physical inactivity with a simple questionnaire can help identify ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...